Clodronate Liposomes Improve Metabolic Profile and Reduce Visceral Adipose Macrophage Content in Diet-Induced Obese Mice

Abstract

BackgroundObesity-related adipose inflammation has been thought to be a causal factor for the development of insulin resistance and type 2 diabetes. Infiltrated macrophages in adipose tissue of obese animals and humans are an important source for inflammatory cytokines. Clodronate liposomes can ablate macrophages by inducing apoptosis. In this study, we aim to determine whether peritoneal injection of clodronate liposomes has any beneficial effect on systemic glucose homeostasis/insulin sensitivity and whether macrophage content in visceral adipose tissue will be reduced in diet-induced obese (DIO) mice.Methodology/Principal FindingsClodronate liposomes were used to deplete macrophages in lean and DIO mice. Macrophage content in visceral adipose tissue, metabolic parameters, glucose and insulin tolerance, adipose and liver histology, adipokine and cytokine production were examined. Hyperinsulinemic-euglycemic clamp study was also performed to assess systemic insulin sensitivity. Peritoneal injection of clodronate liposomes significantly reduced blood glucose and insulin levels in DIO mice. Systemic glucose tolerance and insulin sensitivity were mildly improved in both lean and DIO mice treated with clodronate liposomes by intraperitoneal (ip) injection. Hepatosteatosis was dramatically alleviated and suppression of hepatic glucose output was markedly increased in DIO mice treated with clodronate liposomes. Macrophage content in visceral adipose tissue of DIO mice was effectively decreased without affecting subcutaneous adipose tissue. Interestingly, levels of insulin sensitizing hormone adiponectin, including the high molecular weight form, were significantly elevated in circulation.Conclusions/SignificanceIntraperitoneal injection of clodronate liposomes reduces visceral adipose tissue macrophages, improves systemic glucose homeostasis and insulin sensitivity in DIO mice, which can be partially attributable to increased adiponectin levels.

Antisense Oligonucleotide Treatment Enhances the Recovery of Acute Lung Injury through IL-10–Secreting M2-like Macrophage-Induced Expansion of CD4+ Regulatory T Cells

“…4G, 4H). To confirm the role of macrophages in the expansion of Tregs in vivo, we depleted macrophages in miR-155 ASO-treated ALI mice using clodronate liposomes as reported previously (43). Data showed that compared with the control group, the proliferation of Tregs in the clodronate liposome-treated group decreased significantly on day 4 ( Fig.…”

Efficient Targeting of Adipose Tissue Macrophages in Obesity with Polysaccharide Nanocarriers

“…In fact, TNFα administration is used to induce insulin resistance in mice, and insulin sensitivity can be restored both by pharmacological inhibition of TNFα and reversal of the M2 M1 switch, 7 supporting the damaging role of macrophages and distinguishing them as a target for clinical intervention. [10][11][12] Importantly, visceral adipose tissue (VAT, surrounding the organs) is thought to be the primary site of these pathological effects, as opposed to subcutaneous adipose tissue (beneath the skin). 13 Most clinical treatments for obesity comorbidities, such as insulin or statins, act downstream of inflammatory processes rather than resolving the underlying causes.…”

Bone marrow transplantation as an established approach for understanding the role of macrophages in atherosclerosis and the metabolic syndrome

“…Recent data further strengthen the link between Kupffer cell activation after high-fat feeding, NASH and the development of hepatic insulin resistance [66,67]. The role of activated Kupffer cells on hepatic insulin sensitivity was assessed by depleting Kupffer cells using liposome-encapsulated clodronate in C57BL/6J mice fed a high-fat diet.…”